Literature DB >> 23862168

HFE mutations in Caucasian participants of the Hemochromatosis and Iron Overload Screening study with serum ferritin level <1000 µg/L.

Paul C Adams1, Christine E McLaren, Mark Speechley, Gordon D McLaren, James C Barton, John H Eckfeldt.   

Abstract

BACKGROUND: Many patients referred for an elevated serum ferritin level <1000 µg⁄L are advised that they likely have iron overload and hemochromatosis. AIMS: To determine the prevalence of HFE mutations in the hemochromatosis gene for 11 serum ferritin concentration intervals from 200 µg⁄L to 1000 µg⁄L in Caucasian participants in a primary care, population-based study.
METHODS: The Hemochromatosis and Iron Overload Screening study screened 99,711 participants for serum ferritin levels, transferrin saturation and genetic testing for the C282Y and H63D mutations of the HFE gene. This analysis was confined to 17,160 male and 27,465 female Caucasian participants because the HFE C282Y mutation is rare in other races. Post-test likelihood was calculated for prediction of C282Y homozygosity from a ferritin interval. A subgroup analysis was performed in participants with both an elevated serum ferritin level and transferrin saturation.
RESULTS: There were 3359 male and 2416 female participants with an elevated serum ferritin level (200 µg⁄L to 1000 µg⁄L for women, 300 µg⁄L to 1000 µg⁄L for men). There were 69 male (2.1%) and 87 female (3.6%) C282Y homozygotes, and the probability of being a homozygote increased as the ferritin level increased. Post-test likelihood values were 0.3% to 16% in men and 0.3% to 30.4% in women.
CONCLUSIONS: Iron loading HFE mutations are unlikely to be the most common cause of an elevated serum ferritin level in patients with mild hyperferritinemia. Patients should be advised that there are many causes of an elevated serum ferritin level including iron overload.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23862168      PMCID: PMC3956024          DOI: 10.1155/2013/493170

Source DB:  PubMed          Journal:  Can J Gastroenterol        ISSN: 0835-7900            Impact factor:   3.522


  12 in total

1.  Increased risk of death from iron overload among 422 treated probands with HFE hemochromatosis and serum levels of ferritin greater than 1000 μg/L at diagnosis.

Authors:  James C Barton; J Clayborn Barton; Ronald T Acton; Jeffrey So; Susanne Chan; Paul C Adams
Journal:  Clin Gastroenterol Hepatol       Date:  2012-01-17       Impact factor: 11.382

2.  Liver diseases in the hemochromatosis and iron overload screening study.

Authors:  Paul C Adams; Leah Passmore; Subrata Chakrabarti; David M Reboussin; Ronald T Acton; James C Barton; Gordon D McLaren; John H Eckfeldt; Fitzroy W Dawkins; Victor R Gordeuk; Emily L Harris; Catherine Leiendecker-Foster; Elaine Gossman; Phyliss Sholinsky
Journal:  Clin Gastroenterol Hepatol       Date:  2006-07       Impact factor: 11.382

3.  Relationships of serum ferritin, transferrin saturation, and HFE mutations and self-reported diabetes in the Hemochromatosis and Iron Overload Screening (HEIRS) study.

Authors:  Ronald T Acton; James C Barton; Leah V Passmore; Paul C Adams; Mark R Speechley; Fitzroy W Dawkins; Phyliss Sholinsky; David M Reboussin; Gordon D McLaren; Emily L Harris; Thomas C Bent; Thomas M Vogt; Oswaldo Castro
Journal:  Diabetes Care       Date:  2006-09       Impact factor: 19.112

4.  HFE Cys282Tyr homozygotes with serum ferritin concentrations below 1000 microg/L are at low risk of hemochromatosis.

Authors:  Katrina J Allen; Nadine A Bertalli; Nicholas J Osborne; Clare C Constantine; Martin B Delatycki; Amy E Nisselle; Amanda J Nicoll; Dorota M Gertig; Christine E McLaren; Graham G Giles; John L Hopper; Gregory J Anderson; John K Olynyk; Lawrie W Powell; Lyle C Gurrin
Journal:  Hepatology       Date:  2010-09       Impact factor: 17.425

5.  The diversity of liver diseases among outpatient referrals for an elevated serum ferritin.

Authors:  Karen Wong; Paul C Adams
Journal:  Can J Gastroenterol       Date:  2006-07       Impact factor: 3.522

6.  Hemochromatosis and Iron Overload Screening (HEIRS) study design for an evaluation of 100,000 primary care-based adults.

Authors:  Christine E McLaren; James C Barton; Paul C Adams; Emily L Harris; Ronald T Acton; Nancy Press; David M Reboussin; Gordon D McLaren; Phyliss Sholinsky; Ann P Walker; Victor R Gordeuk; Catherine Leiendecker-Foster; Fitzroy W Dawkins; John H Eckfeldt; Beverly G Mellen; Mark Speechley; Elizabeth Thomson
Journal:  Am J Med Sci       Date:  2003-02       Impact factor: 2.378

7.  Hemochromatosis and iron-overload screening in a racially diverse population.

Authors:  Paul C Adams; David M Reboussin; James C Barton; Christine E McLaren; John H Eckfeldt; Gordon D McLaren; Fitzroy W Dawkins; Ronald T Acton; Emily L Harris; Victor R Gordeuk; Catherine Leiendecker-Foster; Mark Speechley; Beverly M Snively; Joan L Holup; Elizabeth Thomson; Phyliss Sholinsky
Journal:  N Engl J Med       Date:  2005-04-28       Impact factor: 91.245

8.  Hemochromatosis genotypes and risk of iron overload--a meta-analysis.

Authors:  Adriana Maria Neghina; Andrei Anghel
Journal:  Ann Epidemiol       Date:  2010-08-30       Impact factor: 3.797

9.  HFE, SLC40A1, HAMP, HJV, TFR2, and FTL mutations detected by denaturing high-performance liquid chromatography after iron phenotyping and HFE C282Y and H63D genotyping in 785 HEIRS Study participants.

Authors:  James C Barton; Susie A Lafreniere; Catherine Leiendecker-Foster; Honggui Li; Ronald T Acton; Richard D Press; John H Eckfeldt
Journal:  Am J Hematol       Date:  2009-11       Impact factor: 10.047

10.  Screening for hemochromatosis by measuring ferritin levels: a more effective approach.

Authors:  Jill Waalen; Vincent J Felitti; Terri Gelbart; Ernest Beutler
Journal:  Blood       Date:  2007-11-19       Impact factor: 22.113

View more
  5 in total

1.  Plasma ferritin levels, HFE polymorphisms, and risk of pancreatic cancer among Chinese Han population.

Authors:  Zhiming Zhao; Chenggang Li; Minggeng Hu; Jidong Li; Rong Liu
Journal:  Tumour Biol       Date:  2014-05-06

2.  Association of Multiple Biomarkers of Iron Metabolism and Type 2 Diabetes: The EPIC-InterAct Study.

Authors:  Clara Podmore; Karina Meidtner; Matthias B Schulze; Robert A Scott; Anna Ramond; Adam S Butterworth; Emanuele Di Angelantonio; John Danesh; Larraitz Arriola; Aurelio Barricarte; Heiner Boeing; Françoise Clavel-Chapelon; Amanda J Cross; Christina C Dahm; Guy Fagherazzi; Paul W Franks; Diana Gavrila; Sara Grioni; Marc J Gunter; Gaelle Gusto; Paula Jakszyn; Verena Katzke; Timothy J Key; Tilman Kühn; Amalia Mattiello; Peter M Nilsson; Anja Olsen; Kim Overvad; Domenico Palli; J Ramón Quirós; Olov Rolandsson; Carlotta Sacerdote; Emilio Sánchez-Cantalejo; Nadia Slimani; Ivonne Sluijs; Annemieke M W Spijkerman; Anne Tjonneland; Rosario Tumino; Daphne L van der A; Yvonne T van der Schouw; Edith J M Feskens; Nita G Forouhi; Stephen J Sharp; Elio Riboli; Claudia Langenberg; Nicholas J Wareham
Journal:  Diabetes Care       Date:  2016-02-09       Impact factor: 19.112

Review 3.  Hyperferritinemia-A Clinical Overview.

Authors:  Miriam Sandnes; Rune J Ulvik; Marta Vorland; Håkon Reikvam
Journal:  J Clin Med       Date:  2021-05-07       Impact factor: 4.241

4.  Reference intervals established using indirect method for serum ferritin assayed on Abbott Architect i2000SR analyzer in Chinese adults.

Authors:  Qing-Ping Wang; Lin-Ying Guo; Zhi-Yong Lu; Jian-Wen Gu
Journal:  J Clin Lab Anal       Date:  2019-11-01       Impact factor: 2.352

5.  Value of liver iron concentration in healthy volunteers assessed by MRI.

Authors:  Marzanna Obrzut; Vitaliy Atamaniuk; Kevin J Glaser; Jun Chen; Richard L Ehman; Bogdan Obrzut; Marian Cholewa; Krzysztof Gutkowski
Journal:  Sci Rep       Date:  2020-10-21       Impact factor: 4.379

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.